West Pharm Svcs Stock Price, News & Analysis

West Pharmaceutical Services has declared a $0.17 dividend per share for Q1 2021, payable on February 3, 2021. Shareholders of record by January 20, 2021 will receive the dividend. Additionally, the Board has authorized a share repurchase program for up to 631,000 shares in 2021, aimed at enhancing shareholder value. The program will be completed by December 31, 2021. West will also present at the J.P. Morgan Healthcare Conference on January 13, 2021, offering insights into its business.

West Pharmaceutical Services, Inc. (NYSE: WST) has appointed Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary, effective December 8, 2020. She succeeds George L. Miller, who will retire in February 2021. Ms. MacKay joins from The Segal Group, bringing extensive legal experience and knowledge of the regulated pharmaceutical environment, having previously held significant roles at Novartis. The leadership change aims to support West's mission in the injectable drug market, enhancing innovation and compliance.

West Pharmaceutical Services announced a 4Q 2020 dividend increase to $0.17 per share, up from $0.16, marking a 6.25% rise. This dividend is part of the company's commitment to shareholders, representing the 28th consecutive annual increase. The payment will occur on November 18, 2020, for shareholders recorded by November 11, 2020. West's 2019 sales reached $1.84 billion, reflecting ongoing demand for its products in the healthcare sector.

West Pharmaceutical Services, Inc. (NYSE: WST) announced FDA 510(k) clearance and the launch of its Vial2Bag Advanced™ 20mm Admixture Device on Oct. 22, 2020. This innovative, needle-free device facilitates the reconstitution and transfer of medication from vials to IV bags, optimizing pharmacy clean room time and enhancing point-of-care nursing efficiency. Key features include a dual channel design, compatibility with all manufacturers' IV bags, and reduced waste for liquid and powder medications. This advancement supports adherence to USP <797> compounding requirements and aims to improve patient care.

West Pharmaceutical Services (WST) reported a robust third-quarter 2020, achieving net sales of $548.0 million, a 20.1% increase year-over-year. Organic sales grew by 18.2%. The reported diluted EPS rose by 45% to $1.09, with adjusted diluted EPS increasing 46% to $1.15. Full-year sales guidance was raised to between $2.10 billion and $2.11 billion. The company highlighted significant contributions from High-Value Products and Biologics, supported by demand related to COVID-19 treatments and vaccines.

West Pharmaceutical Services, a leader in injectable drug administration solutions, will announce its third-quarter 2020 financial results on October 22, 2020, before market opening. A conference call is scheduled for 9:00 a.m. Eastern Time to discuss the outcomes and future business expectations. Interested participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International), with conference ID 7564183. The call will be available for replay on their website until October 29, 2020.

West Pharmaceutical Services reported Q2 2020 net sales of $527.2 million, a 12.2% increase, with organic sales growth at 14.3%. The diluted EPS rose by 38% to $1.21, with adjusted diluted EPS up 40% to $1.25. The company raised its full-year guidance for net sales to between $2.035 billion and $2.055 billion, and adjusted diluted EPS to $4.15 to $4.25. Strong demand in proprietary and contract-manufactured products, particularly for healthcare devices, bolstered the results.

West Pharmaceutical Services, Inc. (NYSE: WST) announced a dividend of $0.16 per share for the third quarter of 2020. The dividend is scheduled for payment on August 5, 2020, to shareholders of record as of July 29, 2020. This decision underscores the company’s commitment to returning value to its shareholders while continuing its operations in innovative solutions for injectable drug administration.

West Pharmaceutical Services, a leader in injectable drug administration solutions, will reveal its second-quarter 2020 financial results on July 23, 2020, before the market opens. A conference call is scheduled for 9:00 a.m. Eastern Time on the same day to discuss the results and business outlook. Interested participants can join the call by dialing 877-930-8295 or 253-336-8738 for international access, using conference ID 7789173. A live broadcast will also be available on the company’s website.